Literature DB >> 25043657

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer.

XianGuo Chen1, HaiYan Cheng2,3, TengFei Pan1, Yi Liu1, Yang Su1, CuiPing Ren2,3, DaKe Huang3,4, XiaoJun Zha5, ChaoZhao Liang1.   

Abstract

Recently, an increasing number of studies have suggested that mTOR plays a critical role in the regulation of tumor cell motility, invasion and cancer metastasis. However, little is known about the signaling mechanisms in regulating epithelial-mesenchymal transition (EMT) of prostate cancer. In this study, we found that the expression levels of Raptor and Rictor in prostate cancer tissues were elevated, which may suggest that Raptor and Rictor signaling pathways are associated with prostate cancer progression and metastasis. Inhibition of mTORC1 or mTORC2 by knock down of Raptor or Rictor, respectively, migration and invasion of prostate cancer were attenuated. Furthermore, EMT, a characterized by the changed expression levels of various markers like E-cadherin, β-catenin, N-cadherin, and vimentin emergend following inhibition of Raptor or Rictor. Finally, the small GTPases (RhoA and Rac1) which were crucial regulatory proteins in cell migration and invasion were inactivited after downregulating Raptor and Rictor. These results suggest that mTOR regulate EMT at least in part by down regulation of RhoA and Rac1 signaling pathways. Our findings provide novel very attractive target strategies that the inhibition of mTOR signaling pathways may retard prostate cancer migration and invasion at early stages.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  EMT; mTOR; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25043657     DOI: 10.1002/mc.22177

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  24 in total

1.  Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.

Authors:  Banu Iskender; Kenan Izgi; Esra Hizar; Johann Jauch; Aslihan Arslanhan; Esra Hilal Yuksek; Halit Canatan
Journal:  Tumour Biol       Date:  2015-12-30

2.  Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.

Authors:  Smrruthi Vaidegi Venugopal; Silvia Caggia; DaJhnae Gambrell-Sanders; Shafiq A Khan
Journal:  Prostate       Date:  2020-01-29       Impact factor: 4.104

3.  PARP3 comes to light as a prime target in cancer therapy.

Authors:  José Manuel Rodriguez-Vargas; Léonel Nguekeu-Zebaze; Françoise Dantzer
Journal:  Cell Cycle       Date:  2019-05-29       Impact factor: 4.534

4.  Novel role of Giα2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.

Authors:  Silvia Caggia; HimaBindu Chunduri; Ana C Millena; Jonathan N Perkins; Smrruthi V Venugopal; BaoHan T Vo; Chunliang Li; Yaping Tu; Shafiq A Khan
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

Review 5.  Ras, PI3K and mTORC2 - three's a crowd?

Authors:  Stephen F Smith; Shannon E Collins; Pascale G Charest
Journal:  J Cell Sci       Date:  2020-10-08       Impact factor: 5.285

6.  Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.

Authors:  Shang-Jun Jiang; Shuo Wang
Journal:  Tumour Biol       Date:  2015-05-21

7.  EMT changes actin cortex rheology in a cell-cycle-dependent manner.

Authors:  Kamran Hosseini; Annika Frenzel; Elisabeth Fischer-Friedrich
Journal:  Biophys J       Date:  2021-05-20       Impact factor: 3.699

Review 8.  Milk--A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation.

Authors:  Bodo C Melnik
Journal:  Int J Mol Sci       Date:  2015-07-27       Impact factor: 5.923

9.  Evaluation of drug-targetable genes by defining modes of abnormality in gene expression.

Authors:  Junseong Park; Jungsul Lee; Chulhee Choi
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

10.  Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.

Authors:  Jing Chen; Jiawei Guo; Zhi Chen; Jieqiong Wang; Mingyao Liu; Xiufeng Pang
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.